Scott Berry is President and a Senior Statistical Scientist at Berry Consultants, LLC. He earned his PhD in statistics from Carnegie Mellon University and was an Assistant Professor at Texas A&M University before co-founding Berry Consultants in 2000. He is adjunct faculty in the Department of Biostatistics at the University of Kansas Medical Center. Dr. Berry was elected as a Fellow of the American Statistical Association in 2013.

Since 2000, he has been involved in the design of hundreds of Bayesian adaptive clinical trials of pharmaceuticals and medical devices and has become an opinion leader in the field of Bayesian adaptive clinical trials. Some of these trials have been groundbreaking trial designs, setting new standards for innovation and flexibility in trial design. These include the statistical analysis of the first fully Bayesian approval by CDER of the United States FDA (Pravastatin-Aspirin combination), a Bayesian adaptive phase 2 design leading to Lecanemab’s phase 3 trial in sporadic Alzheimer’s disease and eventual FDA approval, and an adaptive phase II/III seamless trial for Dulaglutide (Trulicity) leading to FDA approval in September 2014. He has been involved in the design of multiple adaptive platforms trials, including the global platform trials (REMAP-CAP and ACTIV-4a) in COVID-19.

In addition to his work in biostatistics, Dr. Berry has been recognized as an expert in statistical analyses in sports, with over 40 publications focused on sport applications. He was an author on the 1999 Applications and Case Studies Invited Paper Award from the American Statistical Association for his paper on Bridging different eras in sports and awarded the 2007 Statistics in Sports Award, from the Section on Statistics in Sports of the American Statistical Association.